Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2381700
Max Phase: Preclinical
Molecular Formula: C31H35FN6O6S
Molecular Weight: 638.72
Molecule Type: Small molecule
Associated Items:
ID: ALA2381700
Max Phase: Preclinical
Molecular Formula: C31H35FN6O6S
Molecular Weight: 638.72
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C#CCN(c1cnc(N(CC)CC)nc1N[C@@H](Cc1ccc(OC(=O)N2CCCC2)cc1)C(=O)O)S(=O)(=O)c1ccc(F)cc1
Standard InChI: InChI=1S/C31H35FN6O6S/c1-4-17-38(45(42,43)25-15-11-23(32)12-16-25)27-21-33-30(36(5-2)6-3)35-28(27)34-26(29(39)40)20-22-9-13-24(14-10-22)44-31(41)37-18-7-8-19-37/h1,9-16,21,26H,5-8,17-20H2,2-3H3,(H,39,40)(H,33,34,35)/t26-/m0/s1
Standard InChI Key: GRDNLKHOGQRLIU-SANMLTNESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 638.72 | Molecular Weight (Monoisotopic): 638.2323 | AlogP: 3.99 | #Rotatable Bonds: 13 |
Polar Surface Area: 145.27 | Molecular Species: ACID | HBA: 9 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 12 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 3.09 | CX Basic pKa: 6.47 | CX LogP: 2.83 | CX LogD: 2.57 |
Aromatic Rings: 3 | Heavy Atoms: 45 | QED Weighted: 0.26 | Np Likeness Score: -1.40 |
1. Xu YZ, Konradi AW, Bard F, Dappen M, Dofiles L, Dreyer M, Gallager I, Garrido C, Krimm M, Liao Z, Messersmith E, Mutter L, Pleiss MA, Samant B, Semko CM, Smith J, Stappenbeck F, Stupi B, Vandervert C, Welch B, Wipke B, Yednock T.. (2013) Arylsulfonamide pyrimidines as VLA-4 antagonists., 23 (10): [PMID:23562062] [10.1016/j.bmcl.2013.03.010] |
2. Xu YZ, Smith JL, Semko CM, Rossiter KI, Fukuda JY, Dappen MS, Quincy DA, Konradi AW, Mao W, Welch B, Dreyer ML, Samant B, Zhang H, Lugar J, Liao Z, Henschel C, Petersen E, Vandevert C, Shoemaker M, Wehner N, Mutter L, Shopp G, Krimm M, Chen L, Wipke B, Dofiles L, Gallager I, Sauer JM, Messersmith EK, Pleiss MA, Bard F, Yednock TA.. (2013) Orally available and efficacious α4β1/α4β7 integrin inhibitors., 23 (15): [PMID:23777782] [10.1016/j.bmcl.2013.05.076] |
Source(1):